Lenacapavir, a long-acting injectable PrEP, requires two injections annually, marking a significant advancement in HIV ...
A little specificity would go a long way in the recommendations of the US Preventive Services Task Force (USPSTF)—that is, if we want health insurance companies to pay for lifesaving HIV prevention ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback